Catalog No.
YHK60701
Expression system
E. coli
Species
Homo sapiens (Human)
Protein length
Met1-Leu442
Predicted molecular weight
52.71 kDa
Nature
Recombinant
Endotoxin level
Please contact with the lab for this information.
Purity
>90% as determined by SDS-PAGE.
Accession
Q96SW2
Applications
ELISA, Immunogen, SDS-PAGE, WB, Bioactivity testing in progress
Form
Lyophilized
Storage buffer
Lyophilized from a solution in PBS pH 7.4, 0.02% NLS, 1mM EDTA, 4% Trehalose, 1% Mannitol.
Reconstitution
Reconstitute in sterile water for a stock solution. A copy of datasheet will be provided with the products, please refer to it for details.
Shipping
In general, proteins are provided as lyophilized powder/frozen liquid. They are shipped out with dry ice/blue ice unless customers require otherwise.
Stability and Storage
Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
Alternative Names
Protein cereblon, CRBN, AD-006
HADDOCK-Guided modeling and molecular simulations of cereblon-based ternary complexes: Development of novel PROTACs for Ataxia telangiectasia and RAD3-Related (ATR) kinase., PMID:40516451
Discovery of PZ671, a highly potent and in vivo active CRBN-recruiting Bcl-xL degrader., PMID:40510905
Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor Degradation., PMID:40507351
Covalent Recruitment of NEDD4 for Targeted Protein Degradation: Rational Design of Small Molecular Degraders., PMID:40506832
Rational design and discovery of potent PROTAC degraders of ASK1: a targeted therapy in MASH., PMID:40502626
In-Cell Approach to Evaluate E3 Ligases for Use in Targeted Protein Degradation., PMID:40493706
The contribution of cyclic imide stereoisomers on cereblon-dependent activity., PMID:40443985
Reversing an agonist into an inhibitor: Development of mTOR degraders., PMID:40398155
Targeting transcription factors through an IMiD independent zinc finger domain., PMID:40369156
Discovery of an LSD1 PROTAC degrader., PMID:40366693
Evaluation of anti-leukemic activity and underlying mechanisms of the novel GSPT1 degrader AB138 in acute myeloid leukemia., PMID:40366532
Novel proteolysis-targeting chimera targeting RAD51 for the treatment of triple-negative breast cancer., PMID:40350653
Reductive C(sp2)-C(sp3) Coupling Protocol to Enable Linker Exploration of Cereblon E3-Ligase BRD4 Proteolysis-Targeting Chimeras., PMID:40340429
Discovery and Characterization of RP03707: A Highly Potent and Selective KRASG12D PROTAC., PMID:40338735
Fluorescence-Coupled Ubiquitination Assay as a High-Throughput Screening Strategy for Novel Cereblon Degraders., PMID:40333540
Development of Peptidomimetic PROTACs as Potential Degraders of 3-Chymotrypsin-like Protease of SARS-CoV-2., PMID:40332755
Quantifying Cooperativity through Binding Free Energies in Molecular Glue Degraders., PMID:40326883
Hijacking the MDM2 E3 Ligase with novel BRD4-Targeting PROTACs in Pancreatic Cancer Cells., PMID:40317844
Development of PVTX-405 as a potent and highly selective molecular glue degrader of IKZF2 for cancer immunotherapy., PMID:40312344
Discovery of potent CRBN-recruiting epidermal growth factor receptor (EGFR) degraders in vitro., PMID:40301162
Applications of contemporary tools to measure plasma protein binding of targeted protein degraders., PMID:40286535
Construction of PROTAC molecules by the SuFEx reaction for inducing p300/CBP protein degradation., PMID:40267748
Discovery of a novel molecular glue degrader targeting GSPT1/2 with a non-IMiD-based CRBN binder., PMID:40252382
Structure-Guided Design of ISOX-DUAL-Based Degraders Targeting BRD4 and CBP/EP300: A Case of Degrader Collapse., PMID:40244695
Recent advances in PROTAC-based antiviral and antibacterial therapeutics., PMID:40215946
Rational Design of PROTAC Linkers Featuring Ferrocene as a Molecular Hinge to Enable Dynamic Conformational Changes., PMID:40208910
Self-assembled PROTACs enable glycoproteins degradation in the living cells., PMID:40206552
Thalidomide-induced limb malformations: an update and reevaluation., PMID:40198353
A method for the detection and enrichment of endogenous cereblon substrates., PMID:40196695
PCMT1 generates the C-terminal cyclic imide degron on CRBN substrates., PMID:40196534
A method to identify small molecule/protein pairs susceptible to protein ubiquitination by the CRBN E3 ligase., PMID:40191122
Probing the E3 Ligase Adapter Cereblon with Chemical Biology., PMID:40167161
Development of C646-Based Proteolysis Targeting Chimeras Degraders of the Lysine Acetyltransferases CBP and p300., PMID:40165709
Heterobifunctional proteomimetic polymers for targeted protein degradation., PMID:40161762
Cereblon E3 ligase complex genes are expressed in tissues sensitive to thalidomide in chicken and zebrafish embryos but are unchanged following thalidomide exposure., PMID:40158790
Structure-guided design of a truncated heterobivalent chemical probe degrader of IRE1α., PMID:40151563
Cross-Linking Profiling of Molecular Glue Degrader-Induced E3 Ligase Interactome to Expand Target Space., PMID:40131988
Design, synthesis, and biological evaluation of RIPK1-targeting PROTACs., PMID:40126738
Development of MDM2-Targeting PROTAC for Advancing Bone Regeneration., PMID:40125646
Can we develop effective direct or indirect inhibitors of transcription factors? On the clinical evolution of protein degraders for multiple myeloma therapy., PMID:40122131
Discovery of a Highly Potent and Selective Tyrosine Kinase 2 (TYK2) Degrader with In Vivo Therapeutic Efficacy in a Murine Psoriasis Model., PMID:40116635
Silica-based EGFR-degrading nano-PROTACs for efficient therapy of non-small cell lung cancer., PMID:40113047
Diversity Synthesis Using Glutarimides as Rhodium Carbene Precursors in Enantioselective C-H Functionalization and Cyclopropanation., PMID:40100075
Monoselective Histone Deacetylase 6 PROTAC Degrader Shows In Vivo Tractability., PMID:40063353
Design, synthesis, and biological evaluation of novel BTK-targeting proteolysis targeting chimeras (PROTACs) with enhanced pharmacokinetic properties., PMID:40037061
Nonclinical teratogenicity safety assessment of CRBN-engaging targeted protein degraders: Points to consider., PMID:40015443
PROTAC-induced protein structural dynamics in targeted protein degradation., PMID:40014381
Discovery of a Novel CRBN-Recruiting cGAS PROTAC Degrader for the Treatment of Ulcerative Colitis., PMID:40012371
Unraveling the Engagement of Kinases to CRBN Through a Shared Structural Motif to Optimize PROTACs Efficacy., PMID:40001507
Targeted degradation of GOLM1 by CC-885 via CRL4-CRBN E3 ligase inhibits hepatocellular carcinoma progression., PMID:39986359
For research use only. Not for human or drug use.
